In 2025, everyone enrolled in Part D will have their annual out-of-pocket drug costs capped at $2,000. In future years, that cap will rise in step with the rate of change in Part D costs.

A constitutional challenge to the Biden administration program enabling Medicare to negotiate lower prices for prescription ...

Despite its government spending more than any other on health care both per capita and as a percentage of GDP, spending over $4.5 trillion in 2022, the United States has the lowest life expectancy at ...

A U.S. appeals court revived a lawsuit on Friday by healthcare and drug industry groups challenging the first-ever U.S. law ...

Scientists have devised a free AI algorithm that they believe will make finding new medicines far more efficient.

Utah's life sciences sector is a significant economic powerhouse, but the misguided the Medication Affordability and Patent ...

Granting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...

The drug, nicknamed the ‘Frankenstein’ of opioids, can be up to 500 times more potent than Heroin and 50 times stronger than fentanyl. “It’s been a living hell, you lose your son,” his ...

Shilpa Medicare (SML) climbed 6.12% to Rs 811.25 after the company announced that it has submitted new drug application (NDA) to U.S. Food and Drug Administration (USFDA) for Oxylanthanum Carbonate.

Vice President Kamala Harris is set to propose a handful of new benefits to entrepreneurs ... 2025 and accelerate the speed of Medicare’s drug price negotiations.

has accepted its New Drug Application (NDA) for sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adult ...

KalVista Pharmaceuticals Inc. announced today that the FDA has accepted a New Drug Application (NDA) for oral plasma kallikrein inhibitor sebetralstat to treat hereditary angioedema (HAE) attacks in ...